Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance.
Standard
Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance. / Stöltzing, Oliver.
In: CELL CYCLE, Vol. 9, No. 11, 11, 2010, p. 2051-2052.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
Stöltzing, O 2010, 'Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance.', CELL CYCLE, vol. 9, no. 11, 11, pp. 2051-2052. <http://www.ncbi.nlm.nih.gov/pubmed/20505332?dopt=Citation>
APA
Stöltzing, O. (2010). Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance. CELL CYCLE, 9(11), 2051-2052. [11]. http://www.ncbi.nlm.nih.gov/pubmed/20505332?dopt=Citation
Vancouver
Stöltzing O. Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance. CELL CYCLE. 2010;9(11):2051-2052. 11.
Bibtex
@article{930114d507334df39685bfc42f2ac19c,
title = "Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance.",
author = "Oliver St{\"o}ltzing",
year = "2010",
language = "Deutsch",
volume = "9",
pages = "2051--2052",
journal = "CELL CYCLE",
issn = "1538-4101",
publisher = "LANDES BIOSCIENCE",
number = "11",
}
RIS
TY - JOUR
T1 - Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance.
AU - Stöltzing, Oliver
PY - 2010
Y1 - 2010
M3 - SCORING: Zeitschriftenaufsatz
VL - 9
SP - 2051
EP - 2052
JO - CELL CYCLE
JF - CELL CYCLE
SN - 1538-4101
IS - 11
M1 - 11
ER -
